The United States authorized the use of a new antibody drug against Omicron

2022-06-04 0 By

Washington — U.S. health regulators on Friday approved a new antibody drug for the omicron variant, a key step toward replenishing the national Arsenal for the latest version of the Novel Coronavirus.The US Food and Drug Administration said it cleared the Eli Lilly drug for adult and adolescent patients with mild to moderate novel Coronavirus cases.Lilly announced the treatment late last year after tests showed that its previous antibody treatment did not respond to the dominant microparticle mutation.The Biden administration purchased 600,000 doses ahead of authorization and will begin shipping initial supplies to state health authorities for distribution.Dr. Patricia Cavazzoni, director of the FDA’s Drug center, said it was “an important step toward meeting the need for more tools to treat patients as new variations of the virus continue to emerge.”Prior to the FDA announcement, the two leading monoclonal antibody treatments in the United States had failed to respond to omicron.The data showed that the lily drug was also effective against the emerging ba.2 microparticle mutation.Lilly said the contract for its new drug — bebtelovimab, pronounced “beb-teh-Lo-vi-mab” — is worth at least $720 million.The lab-made Cron antibody represents the body’s immune system by blocking an invading virus.These drugs are given intravenously or by injection and should be used early in the infection.But late last month, the U.S. Food and Drug Administration revoked emergency use authorization for Regeneron’s antibody drug and Lilly.Those two drugs have been the mainstay of antibody therapy, and when doctors didn’t respond to omicron, they had a hard time thinking of pulling back.Alternative therapies, including Antiviral pills from Pfizer and Merck, have been in short supply.Glaxo Skrine also has few antibody drugs that are still effective against Omicron.Novel coronavirus treatments like coronavirus antibodies are not a replacement for vaccination, scientists say.Under the U.S. contract with Lilly, the government will receive about 300,000 new antibody drug treatments in February and about 300,000 treatment courses in March.